5-氯-2-羟基-3-甲基吡啶 | 58498-61-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氯-2-羟基-3-甲基吡啶
• 中文别名: 2-羟基-3-甲基-5-氯吡啶2-HYDROXY-3-METHYL-5-CHLOROPYRIDINE；2-羟基-3-甲基-5-氯吡啶
• 英文名称: 5-chloro-3-methylpyridin-2-ol
• 英文别名: 5-Chlor-3-methyl-pyridin-2-ol；5-chloro-3-methyl-1H-pyridin-2-one
• CAS: 58498-61-6
• 化学式: C₆H₆ClNO
• mdl: MFCD00014592
• 分子量: 143.573
• InChiKey: CBGCPCNUPUGPIF-UHFFFAOYSA-N

物化性质

• 熔点：
  162-163 °C(Solv: benzene (71-43-2))
• 沸点：
  279.6±40.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-氯-2-羟基-3-甲基吡啶 在 三氯氧磷 作用下， 反应 4.0h， 以77%的产率得到2,5-二氯-3-甲基吡啶
  参考文献：
  名称：

  Halogen-substituted pyridines. 3. Cyclization of adducts of ?,?-dichloropropionitrile with acrylic derivatives to chloropyridines

  摘要：

  DOI：

  10.1007/bf00480759
• 作为产物：
  描述：

  Nitrile of 2-Methyl-2,4-dichloro-5-oxopentanoic acid 在 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以51%的产率得到5-氯-2-羟基-3-甲基吡啶
  参考文献：
  名称：

  Halogen-substituted pyridines. 3. Cyclization of adducts of ?,?-dichloropropionitrile with acrylic derivatives to chloropyridines

  摘要：

  DOI：

  10.1007/bf00480759

文献信息

• [EN] MASP-2 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MASP-2 ET PROCÉDÉS D'UTILISATION
  申请人：OMEROS CORP

  公开号：WO2021113686A1

  公开（公告）日：2021-06-10

  The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物以及制备和使用这些化合物的方法。
• [EN] 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS<br/>[FR] DÉRIVÉS DE 4-ÉTHYNYLPYRIDINE UTILES EN TANT QU'INHIBITEURS DE GCN2
  申请人：IP2IPO INNOVATIONS LTD

  公开号：WO2021250399A1

  公开（公告）日：2021-12-16

  The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

  该发明提供了公式I的化合物，其中取代基的详细设置在说明书中进一步详细说明。这些化合物是GCN2的有效抑制剂，具有优异的药代动力学性质。这些化合物可用于治疗或预防各种疾病，特别是癌症。该发明还提供了包括该发明的化合物的药物组合物以及化合物和组合物的用途。
• INFLAMMATORY CYTOKINE RELEASE INHIBITOR
  申请人：MUTO Susumu

  公开号：US20090192122A2

  公开（公告）日：2009-07-30

  A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.

  一种具有抑制NF-κB激活活性的药物，其包括以下通式(I)所表示的化合物或其药理学上可接受的盐作为活性成分：其中X代表连接基，A代表氢原子或乙酰基，E代表芳基或杂芳基，环X代表芳烃或杂芳烃。
• Benzimidazole derivatives and their use as protein kinases inhibitors
  申请人：Berdini Valerio

  公开号：US20070135477A1

  公开（公告）日：2007-06-14

  The invention provides compounds of the formula (1): The compounds have activity against cyclin depdenent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.

  该发明提供了式（1）的化合物： 这些化合物具有对环素依赖性激酶、糖原合成酶激酶和Auroa激酶的活性，因此可用于治疗癌症和病毒性疾病。
• MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：MUTO Susumu

  公开号：US20080234233A1

  公开（公告）日：2008-09-25

  A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.

  这是一种用于预防和/或治疗神经退行性疾病，如阿尔茨海默病等的药物，其包括以下通式（I）所表示的化合物中所选的一种作为活性成分，以及其药学上可接受的盐、水合物和溶剂化合物：其中，A代表氢原子或乙酰基，E代表2,5-二取代或3,5-二取代苯基，或单环或融合的多环杂环芳基，可以取代，但是当所述杂环芳基为圆圈1}在公式（I）中直接结合—CONH—基团的环为苯环，圆圈2}未取代的噻唑-2-基团，或圆圈3}未取代的苯并噻唑-2-基团时，排除在外，环Z代表一个芳烃，除了由公式—O-A所表示的基团和由公式—CONH-E所表示的基团外，还可以有一个或多个取代基，其中A具有上述定义的相同含义，E具有上述定义的相同含义，或者代表一个杂芳烃，除了由公式—O-A所表示的基团和由公式—CONH-E所表示的基团外，还可以有一个或多个取代基。